Generate a tailored SOP for Dr. Walter Lab. Improve your application with a focused, well-structured draft.
Walter Lab focuses on research related to human acute myeloid leukemia (AML). The research team is particularly interested in improving antibody-based therapies for this hematological malignancy by optimizing the efficacy and safety profile of existing therapeutics in both preclinical and early clinical development phases of novel antigen-directed immunotherapies. Recent contributions include the identification of candidate drugs and their preclinical development for five novel agents that have subsequently advanced into clinical testing, such as SGN-CD33A, SGN-CD123A, AMG 330, AMV-564, and APVO436. A major focus of the lab is on delineating the mechanisms of action and resistance of relevant antibody-based AML therapeutics, aiming for the rational development of combination therapies to overcome drug resistance. The lab conducts trials testing novel treatments and innovative care approaches for AML patients and engages in collaborative projects that utilize large patient datasets to develop and improve diagnostic and prognostic tools for people with AML.
Walter Lab • Seattle, WA
Leading research on acute myeloid leukemia (AML) therapies and conducting clinical trials.
Fred Hutch provides training for many UW-affiliated PhD programs. This entry covers the interdisciplinary Molecular and Cellular Biology (MCB) program which encompasses departments like Biology, Medicine, and Human Biology.